News

Public · Published

TD Cowen maintains Alamar Biosciences at Buy, raises price target to $36 from $34

TD Cowen maintained its Buy rating on Alamar Biosciences and raised its price target to $36 from $34, a 5.9% increase. The target implies 19.1% upside from the November 3 closing price of $30.22.

Published:

Updated:

What happened

TD Cowen maintained its Buy rating on Alamar Biosciences and raised its price target to $36 from $34, a 5.9% increase. The target implies 19.1% upside from the November 3 closing price of $30.22.

Confirmed

Global impact / market context

A higher target signals that TD Cowen sees more potential value in Alamar Biosciences shares while keeping its positive rating. If investors act on that view, added demand could support the share price, though the target is an analyst estimate, not a guaranteed outcome.

Analyst inference

The update is an analyst opinion, not a company announcement or a reported change in Alamar Biosciences’ business. Its stated upside compares the target with the November 3 close, so it does not establish that the shares later moved toward that level.

Confirmed

What to watch

  1. Watch for a later change to TD Cowen’s Buy rating or $36 target; another revision would show whether the analyst’s view has strengthened or weakened. Analyst inference
  2. Compare future company updates with the assumptions behind the target, especially any reported changes to revenue, costs, or cash available, if disclosed. Analyst inference
  3. The article gives November 3’s closing price as $30.22 and says the target implies 19.1% upside from that close. Confirmed

Evidence

  • Original source link unavailable